Clinical Trials
3 trialsNCT07471841 2026-06-01
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07411586 2026-05-15
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07153497 2026-05-13
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting